Genitourinary Cancers

11 protocols meet the specified criteria.
  • A031501

    Phase III Randomized Adjuvant Study of MK-3475 in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) versus Observation
  • A031704

    PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)
  • APL-101-01

    Phase 1 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Advanced Solid Tumors and c-Met Dysregulation
  • DB-020-002

    Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeated Doses of DB-020 in Patients Receiving Cisplatin
  • EA8171

    Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer (Phase II)
  • EAY131

    Molecular Analysis for Therapy Choice (MATCH)
  • INCB54828-207

    A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants with Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
  • NRG-GU002

    Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prosatectomy with or without Adjuvant Docetaxel.
  • NRG-GU005

    Phase III IGRT and SBRT versus IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
  • S1806

    Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
  • SIMPRO

    SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology Practice.